Detalhe da pesquisa
1.
Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors.
Bioorg Med Chem Lett
; 27(16): 3817-3824, 2017 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28684121
2.
The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement.
Bioorg Med Chem Lett
; 27(15): 3477-3485, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28629594
3.
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Mol Cancer Ther
; 23(1): 84-91, 2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774393
4.
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.
Mol Cancer Ther
; 22(9): 999-1012, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294948
5.
Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones.
J Org Chem
; 77(8): 3887-906, 2012 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22458369
6.
Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists.
Bioorg Med Chem Lett
; 22(5): 2052-62, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22318156
7.
Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
Bioorg Med Chem Lett
; 22(2): 1055-60, 2012 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22209205
8.
Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives.
Bioorg Med Chem
; 19(19): 5782-7, 2011 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21903403
9.
Correction to "Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement".
ACS Med Chem Lett
; 8(3): 378, 2017 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28337335
10.
Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement.
ACS Med Chem Lett
; 7(12): 1062-1067, 2016 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27994738
11.
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.
J Med Chem
; 58(13): 5189-207, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25970324
12.
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
J Med Chem
; 54(13): 4427-45, 2011 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-21634377